$4.49
2.98% yesterday
Nasdaq, Aug 05, 10:01 pm CET
ISIN
CA25253X2077
Symbol
DMAC

DiaMedica Therapeutics Inc. Stock price

$4.49
+0.86 23.69% 1M
-1.54 25.54% 6M
-0.94 17.31% YTD
+1.04 30.14% 1Y
+2.80 165.68% 3Y
-1.31 22.59% 5Y
+2.91 184.90% 10Y
-21.49 82.71% 20Y
Nasdaq, Closing price Tue, Aug 05 2025
+0.13 2.98%
ISIN
CA25253X2077
Symbol
DMAC
Industry

Key metrics

Basic
Market capitalization
$187.0m
Enterprise Value
$150.7m
Net debt
positive
Cash
$36.3m
Shares outstanding
42.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.5
Financial Health
Equity Ratio
87.9%
Return on Equity
-60.0%
ROCE
-85.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-29.0m | $-40.6m
EBIT
$-29.1m | $-35.6m
Net Income
$-27.0m | $-34.0m
Free Cash Flow
$-22.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-35.3% | -52.4%
EBIT
-35.4% | -33.4%
Net Income
-40.2% | -38.9%
Free Cash Flow
-11.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
8.9%
Employees
28
Rev per Employee
$0.0
Show more

Is DiaMedica Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.

DiaMedica Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a DiaMedica Therapeutics Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a DiaMedica Therapeutics Inc. forecast:

Buy
89%
Hold
11%

Financial data from DiaMedica Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.05 8.05
3% 3%
-
- Research and Development Expense 21 21
60% 60%
-
-29 -29
35% 35%
-
- Depreciation and Amortization 0.04 0.04
33% 33%
-
EBIT (Operating Income) EBIT -29 -29
35% 35%
-
Net Profit -27 -27
40% 40%
-

In millions USD.

Don't miss a Thing! We will send you all news about DiaMedica Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DiaMedica Therapeutics Inc. Stock News

Neutral
Business Wire
about 8 hours ago
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th...
Neutral
24/7 Wall Street
5 days ago
Insider buying has been slow this past month, as buy windows close as the new earnings-reporting season gets underway.
Neutral
Business Wire
13 days ago
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approximately 8.6 millio...
More DiaMedica Therapeutics Inc. News

Company Profile

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Head office Canada
CEO Rick Pauls
Employees 28
Founded 2000
Website www.diamedica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today